Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome

Leukemia and Lymphoma

Volumn 54, Issue 12, 2013, Pages 2671-2677

  Chang, Ying Jun ^a   Zhao, Xiang Yu ^a   Xu, Lan Ping ^a   Liu, Dai Hong ^a   Liu, Kai Yan ^a   Chen, Yu Hong ^a   Wang, Yu ^a   Zhang, Xiao Hui ^a   Zhao, Xiao Su ^a   Han, Wei ^a   Chen, Huan ^a   Wang, Feng Rong ^a   Lv, Meng ^a   Huang, Xiao Jun ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Tsinghua University   (China)

Author keywords

Absolute lymphocyte count; Immune recovery; Lymphocyte recovery; Myelodysplastic syndrome; Transplant outcomes; Unmanipulated haploidentical blood and marrow transplant

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FILGASTRIM; HLA ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL BLOOD AND MARROW TRANSPLANTATION; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CELL TRANSFORMATION, NEOPLASTIC; CHILD; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885932290     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.783912     Document Type: Article

References (35)

1. N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood 2012;119:5632-5639.
2. Parmar S, de Lima M, Deeg HJ, et al. Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol 2011;38:693-704.
3. Chen Y, Liu K, Xu L, et al. HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome. Bone Marrow Transplant 2010;45:1333-1339.
4. Ciurea SO, Champlin RE. Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. Biol Blood Marrow Transplant 2013;19:180-184.
5. Chang YJ, Huang XJ. Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. Curr Opin Hematol 2012;19:454-461.
6. Kim DH, Kim JG, Sohn SK, et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 2004;125:217-224.
7. Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007;21:2145-2152.
8. Savani BN, Rezvani K, Mielke S, et al. Factors associated wiThearly molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006;107:1688-1695.
9. Savani BN, Mielke S, Rezvani K, et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:1216-1223.
10. Chang YJ, Zhao XY, Huo MR, et al. Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. Am J Hematol 2011;86:227-230.
11. Chang YJ, Zhao XY, Huo MR, et al. Influence of lymphocyte recovery on outcome of haploidentical transplantation for hematologic malignancies. Medicine (Baltimore) 2009;88:322-330.
12. Chang YJ, Zhao XY, Huang XJ. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2008;14:323-334.
13. Ciurea SO, Mulanovich V, Jiang Y, et al. Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2011;17: 1169-1175.
14. Federmann B, Hagele M, Pfeiffer M, et al. Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia 2011;25:121-129.
15. Kesserwan C, Munchel A, Kos F, et al. Immune reconstitution after nonmyeloablative, T-cell replete, HLA-haploidentical BMT with posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2011;17:S230-S231.
16. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012;19:324-335.
17. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
18. Chang YJ, Zhao XY, Huo MR, et al. Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol 2012;32:268-280.
19. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304.
20. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graftversus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
21. Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-259.
22. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380-3389.
23. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks:new representations of old estimators. Stat Med 1999;18:695-706.
24. Yan CH, Liu DH, Liu KY, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012;119:3256-3262.
25. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.
26. Nguyen S, Beziat V, Norol F, et al. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation. Transfusion 2011;51:1769-1778.
27. Jacobs NL, Holtan SG, Porrata LF, et al. Host immunity affects survival in myelodysplastic syndromes: independent prognostic value of the absolute lymphocyte count. Am J Hematol 2010;85:160-163.
28. Peggs KS, Thomson K, Samuel E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011;52:49-57.
29. Li N, Matte-Martone C, Zheng H, et al. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood 2011;118: 5965-5976.
30. Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies:posttransplantati on CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009;113:4771-4779.
31. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes:outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002;99:1943-1951.
32. Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome:a retrospective analysis. Lancet Oncol 2011;12:1214-1221.
33. Petersdorf EW. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol 2004;11:386-391.
34. Dong L, Wu T, Zhang MJ, et al. CD3 cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant 2007;13:1515-1524.
35. Zhao XY, Xu LL, Lu SY, et al. IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur J Immunol 2011;41:514-526.